Bugiardini The drugs tell us the truth about vivisection
Bugiardini The drugs tell us the truth about vivisection
Marina Berat , July 2005 - updated December 2007
The package inserts of drugs, those setting out the prescribed dose, the therapeutic indications, contraindications, etc.. are commonly called "Bugiardini. And we can discover from Bugiardini some truth about vivisection more ...
As you know, as a rule of law, any drug to be marketed, it must be tested on healthy volunteers and patients in hospital, but before this is tested on animals. The results of these tests is both estimates of the effects found after the marketing of products, are given in the "Bugiardini", reviewed periodically.
When you read the leaflet that a particular side effect was detected, it is usually not reported if it occurs in humans or animals in the laboratory. Of usually stated explicitly that there was an effect on animals is particularly serious when such animals became ill with cancer. In these cases, the adverse reaction is communicated, specifying, however, that it was found only in animals and humans have a different metabolism, and on them there is no danger. In fact, the drug is marketed in such cases the same, because the approval of the sale of a given drug is not bound in any way the results of animal testing.
Another typical example of an interesting indication of Bugiardini is that of "pregnancy tests" for law the human subjects can not be pregnant women (rightly so), and then reported the package is necessarily related to the animal, unless there have been cases of administration to pregnant women not done on purpose. In these cases, typically it is said "The tests on animals there were no adverse reactions. However, since there are no data for humans, we do not recommend the use of this drug in pregnant woman! And then ... that have made them do tests on animals, if then, whatever their outcome established black and white that it was unnecessary tests that do not give directions to the man?!
These sheets leaflets are therefore useful to show how the movement has been saying for decades antivivisection science: that what happens in animals that is not happening in humans, because an effect may be the same across multiple species (including human) or be different , but it is known in advance! The Bugiardini faramceutiche are written by the companies themselves, thus implicitly admitting that the fallacy of his method of testing.
's so that Bugiardini help us understand the truth about vivisection, a practice which not even the same vivisectors evidently believe ...
In Bugiardini recent years we have collected the most interesting. We report here a collection of the most significant. Who had more to report, send us e-mail the phrase worthy of note, indicating the drug name and the year of review of the leaflet. You can write to info@novivisezione.org. Thanks!
Collecting Bugiardini
Forane
(anesthetic)
Pregnancy
Studies done on rats showed no detrimental effect on fertility, pregnancy, childbirth and vitality of births. Likewise, experiments in rabbits have rabbits vital product, as well as a normal fetal development. It is unknown whether the results of these studies is applicable to humans. Because there is no valid experience on the pregnant woman to have received this drug has not been possible to establish its safety in pregnancy.
Retrovir
do not know what the results of carcinogenicity in rodents are predictive for humans.
Cytotec
A reversible increase in the number of gastric epithelial cell surface normal occurred in dogs, rats and mice. No increase was observed in men who were given Cytotec for one year.
Cefobid
Pregnancy
Reproduction studies have been conducted on mice, rats and monkeys at doses 10 times greater than the dose for humans and not revealed evidence of fertility or harm to the fetus due to CEFOBID. There are, however, adequate and well controlled studies in pregnant women. Because animal reproduction studies are not predictive of human response, this drug should be used during pregnancy only if clearly needed.
Oxcarbamazepina
antiepileptic
2002
There were also found to be teratogenic in mice and rabbits. In one study performed in rats, oxcarbamazepina, daily doses of 300 mg / kg and 1000 mg / kg, caused dose-related teratogenic effects. A developmental toxicity study in mice conducted by Bennett et al. (1996) showed that oral administration of oxcarbamazepina at a dose of 1100 mg / kg (MTD) from 6th to 18th day of gestation led to an incidence of malformations of 8% against 5% observed in the control group. This difference did not reach statistical significance (p> 0.05) but, while taking into account differences in human pregnancy to transpose these data suggest that using the drug during pregnancy only if clearly needed.
There are no data establishing the safety of Tolep (2) in human pregnancy. Similarly, there are no data establishing the safety of Tolep during lactation. We can not exclude the possibility of side effects in children. Both rats mice show a slight increase in the incidence of liver cancer dose-dependent after 2 years of treatment with oxcarbamazepina. On the other hand, the increase of liver tumors seems to be viewed with oxcarbamazepina speciespecifico in rodent and non-related to humans. In addition, the metabolism dell'oxcarbamazepina is very different in experimental animals to man, as the reduction in metabolite MHD is only a minor metabolic pathway.
Aircort nasal spray (budesonide)
(against allergic rhinitis)
Pregnancy
administration of budesonide during pregnancy should be avoided unless there is no particular reason. Studies in animals have teratogenic [ed. that give birth to deformed children] vary depending on the species. Since the relevance of what has been observed in animals to humans has not yet been established in pregnant women is not recommended for use AIRCORT nasal spray especially in the first three months of gestation.
Foy, 100 mg (Gabela Mesylate)
(powder and solvent for solution for infusion)
October 2003
Precautions: In some studies conducted in dogs at high doses, there was a reduction in partial thromboplastin time. This event has not yet been observed during therapy with Foy in humans.
Farlutal
(treatment of secondary amenorrhea, functional menometrorragie)
June 2000
Preclinical safety
toxicity studies long-term studies conducted on monkeys, the dog and the rat, with parenteral administration of medroxyprogesterone acetate, showed the following effects:
beagle dogs, treated at doses of 3 and 75 mg / kg every 90 days to 7 years, developed breast nodules, which were also observed in some control animals.
nodules noted in the control animals were intermittent in nature, while the nodules appeared in animals treated with the drug were bigger, more numerous, persistent character and two of the animals treated at the highest dose developed malignant mammary tumors . Two monkeys treated at a dose of 150 mg / kg every 90 days to 10 years, developed undifferentiated carcinoma of the uterus, which did not exist in monkeys in the control group and those treated at doses of 3 and 30 mg / kg every 90 days to 10 years.
intermittent nature of breast nodules were identified in animals in the control group and those treated at doses of 3 and 30 mg / kg, but not in the group that received a dose of 150 mg / kg.
When autopsy (after 10 years), the nodules were found only in 3 of the monkeys treated group at a dose of 30 mg / kg.
histopathological examination proved that these nodules were hyperplastic in nature. In rats treated for 2 years, there was no evidence of alteration in the uterus and mammary gland.
mutagenesis studies conducted using the test Microsomes Salmonella (Ames test) and Micronucleus test showed that medroxyprogesterone acetate has not no mutagenic activity.
Other studies have shown no change in fertility in the first and second generation of animals observed.
is not yet known whether the above observations may be reported in humans.
Brivirac 125 mg tablets
(early treatment of acute herpes zoster in immunocompetent adults)
October 2004
Preclinical safety data: [.. .] Data from long-term studies on animals, with daily exposure to the drug near the clinical range, are not considered significant for the short-term treatment in humans. Pregnancy and Lactation: Animal studies have shown no embryotoxic or teratogenic effects. Toxic effects on the fetus were observed only at high doses. However, the safety of Brivirac in pregnancy has not been established.
Aliflus spray
(regular treatment of asthma)
December 2004
Preclinical safety data: [...] In animal reproduction studies are glucocorticoids have been shown to induce malformations (cleft palate, skeletal malformations). However, these experimental results do not seem to have any relevance with regard to the administration in humans at recommended doses.
Luan ointment
(lubricant and anesthetic action for introduction of catheters, etc.).
May 1995
Because studies in rats and rabbits treated with topical lidocaine have not shown a risk to the fetus, but has not yet been established its safety in humans, the product should be used with caution in pregnant women, especially in the early stages.
Nimedex
(acute pain)
June 2004
Preclinical safety data: [...] In studies of reproductive toxicity were observed signs of potential teratogenic or embryotoxic (skeletal malformations, dilatation of cerebral ventricles) in rabbits, but not in rats treated up to dose levels not toxic to the mothers. In rats, were observed with increased mortality in the offspring in the early postnatal period and adverse effects on fertility.
Zantipres 7.5 mg tablets
(arterial hypertension)
July 2003
Preclinical safety data: [...] In the carcinogenicity study in mice there was an increased incidence of testicular atrophy, the clinical relevance of this phenomenon is not known.
Pritor 80 mg tablets
(treatment of essential hypertension)
May 2002
Preclinical safety data: [...] In dogs were observed dilation and atrophy of renal tubules. In rats and dogs were also observed gastric mucosal lesions (erosions, ulcers or inflammation). [...] In both species were observed increase in plasma renin activity and hypertrophy / hyperplasia of renal cells iuxtraglomerulari. These alterazionim also an effect of the whole class of ACE inhibitors and other angiotensin II antagonists do not appear to have clinical significance.
Clopidogrel
Pregnancy and Lactation: Reproduction studies in rats and rabbits have revealed no decrease in fertility or fetal harm attributable to clopidogrel. However, there is adequate and controlled studies in pregnant women. Clopidogrel for the lack of data is not recommended during pregnancy.
Onco-carbide
(CML)
June 2000
Special warnings - The product, like how most of anticancer drugs, has shown carcinogenic properties in animals, in particular experimental conditions.
Muscoril capsules
(neuralgia, stiff neck, low back sciatica, Parkinson's disease)
March 1998
Use in pregnancy and lactation:
Although in animal studies has not been observed if not teratogenic when tioclchicoside was administered at doses much higher than those recommended in human therapy (more than 10 times the therapeutic dose) as a precaution the use of the product is contraindicated in pregnancy.
OPTRUMA
Raloxifene hydrochloride
(prevention of osteoporosis in women after menopause)
October 2001
Preclinical safety data: [...] Studies in rats and mice showed an increase in ovarian tumors treated with high doses of medication. In these studies, the female rodents were treated throughout their reproductive lives when their ovaries were functional and highly sensitive to stimulation with sex hormones. In contrast to the high sensitivity of the ovaries in this rodent model, the human ovary after menopause is relatively insensitive to stimulation with sex hormones.
Cardirene
(prevention of coronary thrombosis)
Pregnancy
- in animals: teratogenic effect was observed.
- man: according to several epidemiological studies (especially prospective study in a high number of women) have been found teratogenic effect due to intermittent dosing during the first trimester of pregnancy.
Levoxacin (tablets of 200 and 500 mg)
(treatment of acute sinusitis, bronchitis exacerbation of chronic, community acquired pneumonia, complicated urinary tract infections, skin infections and soft tissue)
Pregnancy
reproduction studies in animals have shown no specific problems. However, in the absence of human data and due to possible damage to the articular cartilage in the growth of organisms exposed to fluoroquinolones, LEVOXACIN tablets should not be used during pregnancy.
Entocir
(treatment of Crohn's disease)
[...] In a further study has not been confirmed the increased incidence of gliomas in the brain of male rats that had occurred in a carcinogenicity study, since the incidence of gliomas was not different among the groups treated with different active ingredients (budesonide , prednisolone, triamcinolone acetonide) and control groups.
Hepatic changes (primary hepatocellular neoplasms) found in male rats in the first carcinogenicity study was confirmed in another study with either budesonide, both with other glucocorticoids for comparison. These effects are probably due to a receptor effect and is therefore typical of the therapeutic class.
clinical experience gained so far does not indicate that budesonide or other glucocorticosteroids induce brain gliomas or primary hepatocellular cancer in humans.
The toxicity of ENTOCIR capsules on the gastrointestinal tract was studied in cynomolgus monkeys after oral administration of repeated doses of up to 5 mg / kg (approximately 25 times the recommended human dose) for up to 6 months. There was no effect on the gastrointestinal tract, or to the macroscopic or histopathologic analysis.
Pregnancy
Administration glucocorticosteroid budesonide in the animal as well as other pregnancy causes abnormalities of fetal development. The relevance of these observations for use in man has not yet been established. As with other drugs, ENTOCIR capsules can be used during pregnancy only after careful evaluation of the risk to the fetus / benefit to the mother.
Ecoval Scal Fluid (betamethasone valerate)
January 2004
Pharmacotherapeutic group: CORTISTEROIDI ACTIVE (GROUP III). Indications: party hair dermatosis such as dermatitis, eczema, seborrheic eczema, psoriasis, alopecia areata, pityriasis dry.
Pregnancy
Topical administration of cortisteroidi to pregnant animals can cause abnormalities in fetal development. The relevance of this experimental data have been found in humans: in pregnant topical steroids should be used in cases of real need and under medical supervision, but not on large areas of skin in large quantities or for prolonged periods.
CLOBESOL 0.5 mg / g cream - 0.5 mg / g ointment (clobetasol propionate)
February 2003
Pharmacotherapeutic group: CORTISTEROIDI VERY ACTIVE (GROUP IV). Indications: Dermatopatie such as psoriasis (excluding widespread plaque psoriasis), recurrent eczema, lichen planus, discoid lupus erythematosus.
Pregnancy
Topical administration of cortisteoridi during pregnancy in laboratory animals can cause abnormalities in fetal development. The relevance of this experimental data have been found in humans: in pregnant topical steroids should be used in cases of real need and under medical supervision, but not on large areas of skin, in large quantities or for prolonged periods.
ANTACAL
(amplodipina, hypertension treatment)
Use in pregnancy and lactation
Animal reproduction studies have shown that amlodipine did not toxic effects, with the exception of parts delayed and prolonged in rats at doses 50 times higher than the maximum dose raccomandta humans.
absence but was still assessing the tolerability of amlodipine in pregnant women or breast-feeding, the use of the product, these circumstances, it is contraindicated.
domperidone
(prokinetic)
Pregnancy
do not have sufficient information to evaluate the potential risk in humans arising from the use of domperidone during pregnancy. Animal studies have shown no adverse effects directly or indirectly related to pregnancy, embryo-fetal development, childbirth or postnatal period. Care must be taken when prescribing domperidone to pregnant women.
NEXIUM, esomeprazole
(treatment for gastroesophageal reflux disease, ulcers, helicobacter pylori)
Use in pregnancy and lactation
order esomeprazole no data are available on exposure during pregnancy.
in studies in animals have not been direct or indirect harmful effects observed at the expense of embryo development.
Animal studies with the racemic mixture do not indicate direct or indirect harmful effects on pregnancy, childbirth and postnatal development. The prescription of the drug to pregnant women must be made with caution.
Pantorc 20 mg
(treatment of mild reflux disease and symptoms related)
October 2002
Preclinical safety data:
In 2 years studies on rodents, and 'an increase in the number of liver tumors in rats (in one study in rats) and in female mice. A slight increase in neoplastic changes of the thyroid and 'was observed in the group of rats receiving the dose more' high in a two-year study. The occurrence of these tumors and the ' associated with changes in the breakdown of thyroxine in the liver in rats. Since 'the therapeutic dose for humans and' low, does not expect side effects on the thyroid glands.
Megestil 160mg
(palliative treatment of endometrial or breast cancer in advanced stages of anorexia-cachexia syndrome in advanced malignancy and AIDS)
Administration of megestrol acetate to female dogs for up to 7 years showed an increase of mammary tumors, whether benign or malignant. On the contrary, in comparative studies studies in rats and monkeys, the incidenz atumorale not 'increased.
Although 'the correlation between canine and human cancers is not well known, it must' be taken into account for assessing the risk / benefit ratio when prescribing Megestil for monitoring the patient.
Isoptin
(acute and chronic coronary heart disease, paroxysmal tachycardia, tachycardia, extrasystoles)
November 2004
SPECIAL WARNING
Since 'animal reproduction studies are not always able to do ein predict the response in humans, the drug should be used during pregnancy only if and' absolutely necessary.
StructoKabiven without
electrolytes (parenteral nutrition in adult patients when oral or enteral administration is not 'possible)
February 2004
Pregnancy and lactation:
The evaluation of data derived from animals has shown toxicity 'reproductive after somminisrtrazione of Structolipid. The clinical relevance of these data are unknown.
Zyloric
(clinical manifestations of deposit of uric acid / urate)
July 2005
Interactions - Tolbutamide:
E 'has been shown that the conversion of tolbutamide to inactive metabolites and' catalyzed by xanthine oxidase of rat liver. Any relief from a clinical point of these observations is not 'known.
Miflonide 200 and 400
(Bronchial asthma)
February 2000
Pregnancy and lactation:
In pregnant animals the administration of corticosteroids has shown cause abnormalities' in fetal development. It 's not yet been established the importance of this finding to humans.
Zofran
(control of nausea and vomiting caused by chemotherapy)
July 2003
SPECIAL WARNING:
The safety of ondansetron in pregnancy in humans has not 'been established. The evaluation of experimental animal studies does not indicate direct or indirect harmful effects on the development Ambri-fetal gestation and development on peri-and post-natal. However, since 'studies are not always predictive of human response, Zofran should not be used during pregnancy.
Unasyn EV
(infection-resistant germs ampicillo)
May 2000
Use in pregnancy and lactation:
Although 'in experiments on laboratory animals have not been observed to be teratogenic, not' UNASYN shown that it can be safely used during pregnancy and during alllattamento.
Aldactazide 25 mg
(oedematous state of secondary hyperaldosteronism)
July 2004
Warning:
Like other substances that interfere activities with 'hormonal spironolactone administered at doses much' higher than therapeutic, and for very prolonged, can 'sometimes be determined in rats an increased incidence of certain types of processes eteroplastici. The current state of scientific knowledge is not 'can be attributed to these comments sure no significance for humans.
Eutimil
(depression, panic attacks, anxiety)
July 2003
Pregnancy and lactation:
Although studies animals have not shown any teratogenic or selective embryotoxic, the safety of paroxetine in pregnant women not 'been established.
Prontalgin drops
(post-chururgico pain, trauma pain, pain attributable to cancer)
May 2003
do not have adequate data safety of tramadol in pregnant women. Glu animal studies have not revealed any toxic effects. Prontalgin drops must not be used in pregnancy during labor in childbirth and breastfeeding.
Topmax
(epilepsy)
February 2004
Pregnancy and lactation:
Topiramate, like other antiepileptic drugs, and is' teratogenic in animals. There are no studies on the use of topiramate during pregnancy. Postmarketing experience, have been reported cases of hypospadias in male infants exposed to topiramate during pregnancy, even in combination with other antiepileptic drugs. It 's not been given a direct causal relationship with topiramate.
Ecoval
(dermatitis)
February 2006
Pregnancy and lactation:
Topical administration of corticosteroids during pregnancy in laboratory animals can result in animals in fetal development. The relevance of this experimental data have been found in humans.
Limican
(antiemetic)
July 2005
Pregnancy and lactation:
Although experiments carried out with alizapride on various animal species have not shown teratogenic effects, as a precautionary measure and in the absence of epidemiological studies, the alizapride should not be prescribed during pregnancy.
Antacal 5
(hypertension)
May 1998
Pregnancy and lactation:
Animal reproduction studies have shown that 'amlodipine has no toxic effects, except share and prolumgati delayed in rats at doses 50 times higher than the maximum recommended human dose. However, the absence of yet been established tolerability of amlodipine in pregnant women or breast-feeding, the use of the product, in these circumstances is contraindicated.
Elopram
(depressive syndrome)
December 2005
precautions for use:
Although animal studies have not shown for citalopram potential epileptogenic like other antidepressants, citalopram should be used with caution in patients with a history of seizures.
Kimono
(antibacterial)
May 2005
Interaction
In mice, co-administered with fenbufen, a dose 10 times higher than treatment, induced the appearance of convulsive events. Although there is no clinical evidence of an interaction between fenbufen and chimeras, their coadministration should be avoided.
Ratacand
(hypertension)
December 2004
Use during lactation:
is not known whether candesartan is excreted in breast milk. However, candesartan is excreted in the milk of lactating rats.
Zirtec
(epilepsy)
April 2006
Pregnancy and lactation:
No adverse effect was observed during the animal studies. Knowledge about use of cetirizine during pregnancy are limited. As with other drugs, somminstrazione woman in her pregnant should be avoided.
Daparox
(antidepressant)
March 2006
Pregnancy
Some epidemiological studies have shown a slight increase in the risk of cardiovascular malformations [newborn] [...] association with taking paroxetine during the first trimester of gravidenza. [...] Paroxetine should be used during pregnancy only when clearly indicated. [...] The infant must be observed if maternal use paroxetine continues in the later stages of pregnancy, especially in the third quarter. The following symptoms may occur in infants after maternal use of paroxetine in the later stages of pregnancy: respiratory distress (presence of severe respiratory difficulties resulting in inadequate oxygenation of the blood), cyanosis, apnea, seizures, temperature instability, difficulty in 'feeding, vomiting, hypoglycaemia, hypertonia, hypotonia, iperrefressia, tremor, nervousness, irritability, lethargy, constant crying, sleepiness and difficulty falling. [...] Animal studies have shown reproductive toxicity, but did not indicate direct harmful effects with respect to pregnancy, embryo-fetal development, parturition or postnatal development.